Everline Bosek is a project management professional with experience in implementation research, HIV activities and community health. She has worked in western Kenya implementing community health and mobile health projects. She later worked as a national coordinator for a malaria project using a community health approach. Everline has experience in stakeholder management, training coordination and program management.
Dr. Valentina Cambiano has worked in design and analysis of HIV observational study research, in mathematical modelling of HIV epidemics and in cost effectiveness analyses. Dr. Cambiano is a Research Associate in the Department of Infection & Population Health at the Institute of Epidemiology & Health Care at University College London.
Dr. Bhavna Chohan has over 25 years of experience with HIV/STD research. Dr. Chohan has conducted research on antiretroviral resistance in early treated HIV-infected infants and early transmitted HIV variants in HIV discordant couples. She is currently the Laboratory Director conducting research on HIV/AIDS as co-investigator for the collaborative research studies at University of Nairobi, and mentors students and junior staff. She holds a Visiting Scientist and Honorary Lecturer position at University of Nairobi, Senior Research Scientist in the Center for Virus Research at Kenya Medical Research Institute, and an Acting Assistant Professor position in the Department of Global Health at University of Washington.
Dr. Megan Dunbar is an expert consultant in the areas of research, policy advocacy, program evaluation, in particular for initiatives that aim to promote access to HIV prevention and treatment for key affected populations with a special emphasis on ARV-based prevention technologies. From April 2010 through March 2016, Dr. Dunbar was Chief Programs Officer at Pangaea Global AIDS. During much of that time, Dr. Dunbar was resident in Harare, Zimbabwe where she worked to establish Pangaea Zimbabwe AIDS Trust which partners with the Ministry of Health and Child Care, civil society, and research groups, to expand access to HIV services for underserved communities in Zimbabwe.
Dr. Rick Homan is a scientist with extensive training and experience in evaluating the efficiency and effectiveness of health care delivery systems. Currently he is working on projects ranging from assessing the cost and effectiveness of service delivery interventions for family planning, reproductive health and HIV/AIDS to assessing the efficiency of HIV/AIDS service delivery in Zambia. Dr. Homan is a Health Economics Scientist in the Health Services Research Department at FHI 360.
Lauren Kudrick has project management experience in multiple international research projects, ranging from social sciences to the health sciences fields. She has experience in fiscal oversight and budget, project and materials management in both for-profit and non-profit settings. Ms. Kudrick is a Project Manager for the HIV/AIDS Program, Division of Infectious Diseases, at the University of Pittsburgh.
Lisa Levy has experience working on clinical trials that measure resistance to microbicides and pre-exposure prophylaxis (PrEP) study products, including MTN-003 (VOICE), a Phase IIB randomized clinical trial that enrolled more than 5000 participants across South Africa, Zimbabwe, and Uganda. She also led MTN-015, an observational cohort study of women following HIV-1 seroconversion in a microbicide trials study. Ms. Levy is a Senior Clinical Research and Project Manager with Science Facilitation at FHI 360.
Dr. Kevin McCormick is a Postdoctoral Research Associate in the Division of Infectious Diseases at the University of Pittsburgh.
Dr. John Mellors has studied HIV drug resistance for over 25 years and has made significant contributions to understanding mechanisms of HIV resistance, development and interpretation of resistance diagnostics, clinical significance and management of major and minor drug-resistant variants, and modeling of the potential impact of HIV drug resistance arising from antiretroviral therapy and pre-exposure prophylaxis (PrEP) on therapeutic and preventive efficacy. Dr. Mellors is a tenured Professor of Medicine, Pathology, and Infectious Diseases and Microbiology, and Chief of the Infectious Diseases Division at the University of Pittsburgh.
Dr. Fumiyo Nakagawa has worked in statistical analyses of HIV observational studies and in mathematical modelling of European HIV epidemics. Dr. Nakagawa is a Research Assistant in the Department of Infection & Population Health at the Institute of Epidemiology & Health Care at University College London.
Dr. Urvi Parikh has worked in the HIV/AIDS field for the past 18 years. She has expertise in virology and molecular biology in the context of clinical and translational research and her laboratory conducts endpoint validation for seroconverters from microbicide trials, viral load testing, HIV diagnostic testing and algorithm improvement, HIV standard genotyping and phenotyping on non-B subtypes, and sensitive resistance testing (allele-specific PCR). Dr. Parikh is the Associate Director of the Virology Core Microbicide Trials Network and an Assistant Professor of Medicine in the Division of Infectious Diseases at the University of Pittsburgh.
Kerri Penrose has over 10 years of experience designing, leading and conducting molecular biology/virology based projects. She has served as a consultant in the development of a state of the art HIV-1 full-length reverse transcriptase genotypic assay that is now being employed as a standard HIV genotypic test for several labs. Ms. Penrose is a Research Project Manager in the Division of Infectious Diseases at the University of Pittsburgh.
Jill Peterson has over 15 years of experience in research, program evaluation, and monitoring and evaluation (M&E). She has overseen research projects evaluating the effectiveness of program interventions aimed to increase demand for and access to family planning and projects related conservation agriculture, food-for work, cash-for-work, and community garden activities. She has experience supervising staff and managing teams internationally. Ms. Peterson is the Team Lead for Monitoring & Evaluation and Operations Research on various projects at FHI 360.
Dr. Andrew Phillips has worked extensively in design and analysis of HIV observational study research as well as randomized trials and in simulation modelling and cost effectiveness evaluations. Dr. Phillips is a Professor of Epidemiology and Biostatistics in the Department of Infection & Population Health at the Institute of Epidemiology & Health Care at University College London.
Dr. Barbra Richardson has over 20 years of experience as a lead statistician on numerous HIV/STD clinical trials and observational studies. These include studies of mother to child HIV transmission, microbicides for prevention of HIV and other STDs, HIV disease progression, correlates of HIV risk and acquisition, and HIV treatment studies. Barbra Richardson is Joint Member in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center, Research Professor in the Department of Biostatistics and Adjunct Research Professor in the Department of Global Health at the University of Washington.
Dr. Raquel Viana has over 7 years of experience in the HIV Drug Resistance field of study and is involved in several clinical trial networks in the field. In her current role at Lancet/BARC-SA she is involved in routine testing procedures, assay implementation, overseeing of QC monitoring and implementation thereof once new assays are employed, costing and marketing of assays within Molecular Pathology and is part of the senior management tasked with overseeing all work carried out within the department. Dr. Viana is a Senior Medical Scientist at Lancet Laboratories and BARC-SA.
Dr. Carole Wallis has over 10 years of experience in molecular diagnostic assays related to HIV, Hepatitis B and TB. She has carried out several studies looking at the development of drug resistance patterns in Sub-Saharan Africa, Eastern and Western Africa covering all major subtypes in those regions (HIV-1 subtype C, D, A and AG); the impact these mutations will have on newer antiretroviral compounds and the use of different diagnostic assays to detect these mutations. Dr. Wallis is Head of the Specialty Molecular Division for Lancet/BARC-SA.
Dr. Irina Yacobson has over 29 years of clinical experience, including 10 years in non-communicable diseases and 19 years in reproductive health field, including HIV. She has planned and implemented clinical workshops for health care providers around the world and conducted training in family planning, adolescent reproductive health, sexually transmitted infections, family planning/HIV integration, study-specific procedures, and evidence-based medicine. Dr. Yacobson is a Technical Advisor II in the Global Health, Population & Nutrition Department of FHI 360.